Pierre N Tariot, Lon S Schneider, Jeffrey Cummings, Ronald G Thomas, Rema Raman, Laura J Jakimovich, Rebekah Loy, Barbara Bartocci, Adam Fleisher, M Saleem Ismail, Anton Porsteinsson, Michael Weiner, Clifford R Jack, Leon Thal, Paul S Aisen
CONTEXT: Agitation and psychosis are common in Alzheimer disease and cause considerable morbidity. We attempted to delay or to prevent agitation and psychosis with the use of divalproex sodium (valproate). OBJECTIVE: To determine whether treatment with valproate could delay or prevent emergence of agitation or psychosis. DESIGN, SETTING, AND PATIENTS: A multicenter, randomized, double-blind, placebo-controlled trial of flexible-dose valproate in 313 (of 513 screened) individuals with moderate Alzheimer disease who had not yet experienced agitation or psychosis...
August 2011: Archives of General Psychiatry